Clinical Cooperation Group Molecular Oncology, Klinikum der Universität München and Helmholtz Zentrum München, Marchioninistrasse 25, Munich, Germany.
Eur J Cell Biol. 2012 Jan;91(1):97-101. doi: 10.1016/j.ejcb.2011.04.001. Epub 2011 Jun 2.
Adoptive T cell therapy is the transfer of T cells to a patient in order to combat disease. This procedure is mainly being used but not limited to the treatment of viral infections and malignancies including virus-associated tumors. Depending on the clinical context, the T cell donor may be the same patient or another donor, usually a healthy person. Recent research is centered on the use of antigen-specific T cells, but T cells of uncharacterized specificity can be successfully used in some clinical conditions where target antigens are not known. Depending on underlying scientific hypotheses and preferred technologies, the therapeutic T cells may be anything from monoclonal to highly polyclonal; they may be specific for one epitope, several epitopes from one antigen, or various antigens; they may have been selected during the preparation process for their specificity, their functional capacity, their survival and proliferation in vitro, or the expression of surface markers associated with desirable functional properties. In this minireview, we give a brief overview on selected approaches, problems and solutions in adoptive T cell therapy. We focus on an area where T cell therapy has been particularly successful but is still calling for improvement: herpesviral disease in patients after transplantation.
过继性 T 细胞疗法是将 T 细胞转移给患者以对抗疾病。该程序主要用于治疗病毒感染和恶性肿瘤，包括病毒相关肿瘤，但不限于这些疾病。根据临床情况，T 细胞供体可以是同一患者或另一个供体，通常是健康人。最近的研究集中在抗原特异性 T 细胞的使用上，但在一些靶抗原未知的临床情况下，未鉴定特异性的 T 细胞也可以成功使用。根据潜在的科学假设和首选技术，治疗性 T 细胞可以是单克隆的，也可以是高度多克隆的；它们可以针对一个表位，也可以针对一个抗原的几个表位，或者针对各种抗原；它们在制备过程中可能因其特异性、功能能力、体外生存和增殖能力，或与理想功能特性相关的表面标志物的表达而被选择。在这篇综述中，我们简要概述了过继性 T 细胞疗法的一些方法、问题和解决方案。我们重点关注一个在过继性 T 细胞疗法中取得特别成功但仍需要改进的领域：移植后患者的疱疹病毒病。
